此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于治疗慢性肢体威胁性缺血患者腘下动脉疾病的可吸收依维莫司洗脱支架 (RESCUE)

可吸收依维莫司洗脱支架用于治疗慢性肢体威胁性缺血患者腘下动脉疾病

RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg.

These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving temporary structural support to the vessel. Over time, the scaffold naturally dissolves in the body, which may lower the long-term risks associated with permanent metal stents.

研究概览

研究类型

观察性的

注册 (估计的)

400

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Claire Poulet, PhD
  • 电话号码:+41 79 385 16 78
  • 邮箱:oracue@cirse.org

研究联系人备份

  • 姓名:Dhwani S. Korde, PhD
  • 电话号码:+4367762942469
  • 邮箱:oracue@cirse.org

学习地点

      • Hull、英国、HU3 2JZ
        • 招聘中
        • Hull University Teaching Hospitals NHS Trust
        • 首席研究员:
          • Raghu Lakshminarayan, Dr

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adult CLTI patients treated with the Esprit BTK everolimus-eluting resorbable scaffold following adequate vessel preparation for infrapopliteal artery disease.

描述

Inclusion Criteria:

  1. Rutherford classification category ≥4;
  2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation;
  3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
  4. Patients competent and willing to provide informed consent.

Exclusion Criteria:

  1. Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
  2. Inadequate inflow (>30% stenosis) following optimization;
  3. Insufficient direct outflow (less than 1 run-off vessel);
  4. Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
  5. Patients planned to receive an above ankle amputation of the target limb;
  6. Patients enrolled in ORACLE (ClinicalTrials.gov ID NCT07270562).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Adult CLTI patients with infrapopliteal calcified lesions

Adult CLTI patients planned to receive the Esprit BTK™ resorbable scaffold following pre-dilatation with angioplasty balloon.

The Esprit BTK™ is a bioresorbable vascular scaffold designed for arteries below the knee. It provides temporary support to keep the vessel open while releasing everolimus-an antiproliferative drug that helps prevent excessive tissue growth and reduces the risk of restenosis. As the scaffold delivers the medication, it gradually dissolves, potentially lowering long-term risks associated with permanent stents.

其他名称:
  • 药物洗脱可吸收支架

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of lesions free from Clinically-Driven Target Lesion Revascularization (CD-TLR)
大体时间:12 months

Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

12 months

次要结果测量

结果测量
措施说明
大体时间
CD-TLR-free survival per target lesion
大体时间:Until the end of the follow-up period of 3 years

Defined as the time between first index procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

Until the end of the follow-up period of 3 years
Clinical response using Rutherford classification categories
大体时间:12, 24, and 36 months

The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.

12, 24, and 36 months
Wound status
大体时间:12, 24, and 36 months

Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).

12, 24, and 36 months
Freedom from major amputation of the target limb
大体时间:12 and 24 months

Defined as absence of any amputation of the target limb (above ankle).

12 and 24 months
Amputation-free survival
大体时间:Until the end of the follow-up period of 3 years

Defined as time between first index procedure and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the index procedure).

Until the end of the follow-up period of 3 years
Overall survival
大体时间:Until the end of the follow-up period of 3 years

Defined as the time between the first index procedure and death of any cause.

Until the end of the follow-up period of 3 years
Patient-reported health-related quality-of-life
大体时间:Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment

Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.

Baseline, Day 0 (day of procedure), 6-, 12-, 24-, 26-months post treatment
Frequency and severity of procedural complications and other adverse events
大体时间:Within 30 days after the index procedure

Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.

Within 30 days after the index procedure
Frequency of major adverse limb events (MALE) and peri-operative death (POD).
大体时间:6 months for MALE; Within 30 days after the index procedure for POD

MALE include above-ankle amputation in the index limb, major re-intervention on the index limb at 6 months and POD includes perioperative (30-day) mortality.

6 months for MALE; Within 30 days after the index procedure for POD
Clinical response using ankle-brachial index (ABI)
大体时间:12, 24, and 36 months

The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.

12, 24, and 36 months
Clinical response using toe pressure
大体时间:12, 24, and 36 months

The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.

12, 24, and 36 months
Clinical response using WIfi (wound, ischemia and foot infection) score
大体时间:12, 24, and 36 months

The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.

12, 24, and 36 months
Restoration of normal lumen per target lesion
大体时间:Immediately upon procedure completion

Defined as residual stenosis ≤30%, immediately after completion of full planned procedure.

Immediately upon procedure completion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 学习椅:Gerd Grözinger, Prof. Dr. med.、SLK Kliniken Heilbronn GmbH
  • 学习椅:Marianne Brodmann, Univ.-Prof. Dr. med.、Medizinische Universität Graz
  • 学习椅:Raghu Lakshminarayan, Dr、Hull University Teaching Hospital
  • 学习椅:Stefan Müller-Hülsbeck, Prof. Dr. med.、DIAKO Krankenhaus gGmBH

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月31日

初级完成 (估计的)

2032年8月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2025年11月19日

首先提交符合 QC 标准的

2025年11月26日

首次发布 (实际的)

2025年12月8日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅